Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

3SBio Acquires Global Rights to Apexigen RA Drug

publication date: Jun 22, 2015
China's 3SBio obtained global rights to an anti-TNF mAb for autoimmune disease, including rheumatoid arthritis, which was discovered by Apexigen of the San Francisco area. 3SBio in-licensed China rights to SSS07 in 2006; the new pact extends that agreement to include the rest of the world. 3SBio started a China Phase I trial of the molecule earlier this year. The ex-China rights will allow 3SBio to bring the drug to the lucrative US and European markets. No financial details were disclosed. More details....

Stock Symbol: (HKEX: 1530)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital